Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors.

Pfizer CEO Albert Bourla called vaccine skepticism in the highest levels of the federal government “an anomaly” during an investor call on Tuesday. “We will continue investing in vaccines because, as ...